Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

2015 ◽  
Vol 11 (23) ◽  
pp. 3159-3166 ◽  
Author(s):  
Annalisa Guida ◽  
Cristina Masini ◽  
Michele Milella ◽  
Giuseppe Di Lorenzo ◽  
Matteo Santoni ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Metastatic Renal Cancer ◽  
Safety And Efficacy

A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

2010 ◽  
Vol 33 (9) ◽  
pp. 991-998 ◽  
Author(s):  
Olivier Adotevi ◽  
Helene Pere ◽  
Patrice Ravel ◽  
Nacilla Haicheur ◽  
Cecile Badoual ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Antiangiogenic Therapy ◽  
Metastatic Renal Cancer

Immunoendocrine Therapy with Interleukin-2 (IL-2) and Medroxyprogesterone Acetate (MPA): A Randomized Study with or without MPA in Metastatic Renal Cancer Patients during IL-2 Maintenance Treatment after Response or Stable Disease to IL-2 Subcutaneous Therapy

1993 ◽  
Vol 79 (4) ◽  
pp. 246-249 ◽  
Author(s):  
Paolo Lissoni ◽  
Sandro Barni ◽  
Gabriele Tancini ◽  
Fernando Brivio ◽  
Paolo Cardellini ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Stable Disease ◽  
Medroxyprogesterone Acetate ◽  
Low Dose ◽  
Interleukin 2 ◽  
Cytotoxic Lymphocytes ◽  
Metastatic Renal Cancer ◽  
Significant Difference

Aims and Background It is known that interleukin-2 (IL-2) activated cytotoxic lymphocytes require a cell-cell contact to exert their anticancer action. Therefore, the pronounced fibrosis that generally characterizes the neoplastic mass could counteract the action of cytotoxic lymphocytes. Some preliminary studies have shown that progesterone and its analogs may inhibit fibroblast proliferation. On the basis of such evidence, we have designed a clinical study with or without the progestational agent medroxyprogesterone acetate (MPA) in metastatic renal cancer patients in maintenance therapy with IL-2 following response or stable disease (SD) after two cycles of IL-2 subcutaneous immunotherapy, in an attempt to evaluate the influence of MPA on free-from progression (FPP) period. Methods The study included 30 consecutive patients who were randomized to receive IL-2 alone (3 mllion IU twice/day for 5 days/month subcutaneously) or IL-2 plus low-dose MPA (500 mg orally one day/week) without interruption until disease progression. Results A FPP period longer than 1 year was obtained in 8/14 patients treated with IL-2 plus MPA and in only 3/16 patients treated with IL-2 alone. The difference was statistically significant. On the contrary, no significant difference was seen in the mean number of lymphocytes and eosinophils, which was evaluated monthly. Finally, no hyperglycemic or thromboembolic complications occurred in patients concomitantly treated with MPA. Conclusions This preliminary study would suggest that the concomitant administration of low-dose MPA may prolonge the FFP period in metastatic renal cancer patients under maintenance therapy with IL-2. A longer follow-up will be required to evaluate the influence of MPA on overall survival.

scholarly journals Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting

2009 ◽  
Vol 44 (4) ◽  
pp. 237-242 ◽  
Author(s):  
M Bregni ◽  
M Bernardi ◽  
P Servida ◽  
A Pescarollo ◽  
R Crocchiolo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cancer ◽  
Metastatic Renal Cancer ◽  
Long Term Follow Up ◽  
Reduced Intensity

scholarly journals Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

2010 ◽  
Vol 16 (22) ◽  
pp. 5539-5547 ◽  
Author(s):  
Robert J. Amato ◽  
Robert E. Hawkins ◽  
Howard L. Kaufman ◽  
John A. Thompson ◽  
Piotr Tomczak ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cancer ◽  
Phase Iii ◽  
Metastatic Renal Cancer ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Phase Iii Study

scholarly journals Real world experience of nivolumab therapy in metastatic renal cancer patients: A 3 year multi-centre review

2019 ◽  
Vol 30 ◽  
pp. v389
Author(s):  
J. Hack ◽  
S.L. Hill ◽  
J. Broadfoot ◽  
C. Chau ◽  
T. Geldart ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cancer ◽  
Real World ◽  
Metastatic Renal Cancer
Sign in / Sign up

Export Citation Format

Share Document